Edition:
India

Bellicum Pharmaceuticals Inc (BLCM.OQ)

BLCM.OQ on NASDAQ Stock Exchange Global Market

6.20USD
23 Oct 2020
Change (% chg)

$0.08 (+1.31%)
Prev Close
$6.12
Open
$6.20
Day's High
$6.50
Day's Low
$6.02
Volume
5,480
Avg. Vol
14,597
52-wk High
$27.80
52-wk Low
$3.32

Latest Key Developments (Source: Significant Developments)

Bellicum Pharmaceuticals Reports Q2 2019 Results
Tuesday, 6 Aug 2019 

Aug 5 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM PHARMACEUTICALS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES OPERATIONAL UPDATE.QTRLY LOSS PER SHARE $0.58.  Full Article

Bellicum Reports Safety Results For Pancreatic Cancer Drug
Friday, 14 Dec 2018 

Dec 14 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM REPORTS SAFETY RESULTS AND PROMISING ACTIVITY OF ITS CONTROLLED CAR-T CANDIDATE BPX-601 IN PATIENTS WITH ADVANCED PANCREATIC CANCER AT ESMO-IO.BELLICUM PHARMACEUTICALS INC - BPX-601 WAS WELL-TOLERATED WITH NO CRS OR NEUROTOXICITY REPORTED IN INITIAL CELL-DOSE ESCALATION.BELLICUM PHARMACEUTICALS INC - INITIAL EVIDENCE OF BIOLOGIC ACTIVITY AND STABLE DISEASE OBSERVED IN SOME PATIENTS WITH SINGLE RIMIDUCID DOSE.BELLICUM PHARMACEUTICALS INC - RIMIDUCID-ACTIVATED GOCAR-T(®) RESULTED IN SIGNIFICANT EXPANSION AND PERSISTENCE OF T CELLS.BELLICUM PHARMACEUTICALS INC - TO ADD ADDITIONAL TUMOR TYPES IN PART 2 OF STUDY, INCORPORATING STANDARD LYMPHODEPLETION AND REPEAT RIMIDUCID DOSING.BELLICUM PHARMACEUTICALS INC - LOOK FORWARD TO REPORTING UPDATED RESULTS OF BPX-601 STUDY IN 2019.  Full Article

Bellicum Pharmaceuticals Appoints Atabak Mokari As CFO
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM PHARMACEUTICALS APPOINTS ATABAK MOKARI AS CHIEF FINANCIAL OFFICER.BELLICUM PHARMACEUTICALS INC - APPOINTMENT OF ATABAK MOKARI AS CHIEF FINANCIAL OFFICER, EFFECTIVE DECEMBER 19.BELLICUM PHARMACEUTICALS INC - MOKARI JOINS BELLICUM FROM IRIDEX CORPORATION.  Full Article

BRIEF-Bellicum Pharmaceuticals Got Approval From Nasdaq to Transfer Listing Of Common Stock

* BELLICUM PHARMACEUTICALS - ON JUNE 16, GOT APPROVAL FROM NASDAQTO TRANSFER LISTING OF COMMON STOCK FROM NASDAQ GLOBAL MARKET TO NASDAQ CAPITAL MARKET